Gradalis, Inc.
Gradalis, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Gradalis, Inc..
Gradalis, Inc. is a company.
Key people at Gradalis, Inc..
Key people at Gradalis, Inc..
Gradalis, Inc. is a late-stage clinical biotechnology company headquartered in Carrollton, Texas, specializing in personalized cancer immunotherapies.[1][4] It develops Vigil (gemogenovatucel-T), a proprietary bi-shRNA DNA-based plasmid immunotherapy platform that uses a patient's own tumor tissue to train the immune system against cancer cells, targeting solid tumors like ovarian cancer and Ewing's sarcoma.[1][3][4] The therapy addresses unmet needs in advanced cancers by offering a patient-specific "trifecta" of anti-cancer activity, with Phase 3 trials cleared for ovarian cancer (VITAL-V study planned for late 2023) and potential expansion to other indications.[1][3] Serving oncology patients and physicians, Gradalis solves the problem of tumor recurrence and resistance in immunotherapy through customization, demonstrating clinical success in trials while generating ~$8.7 million in revenue with 44 employees.[1]
Founded in 2006, Gradalis emerged as a privately held biotech firm pioneering bi-shRNA technology for personalized cancer therapies.[3][4] Key details on specific founders are not detailed in available sources, but the company quickly advanced its Vigil platform from early research, focusing on immunotherapy for solid tumors.[1][3] Pivotal moments include FDA clearance in December 2022 for the Phase 3 VITAL-V trial in advanced ovarian cancer, building on prior Phase 1/2 data in Ewing's sarcoma (pGBI-140) and other indications like solid tumors via stathmin inhibitors.[1][3] Early traction came from proprietary methods enhancing treatment efficacy, evolving from preclinical bi-shRNA-KRAS efforts to late-stage commercialization.[2][3]
Gradalis stands out in oncology biotech through these key strengths:
Gradalis rides the personalized medicine and immunotherapy wave in oncology, where neoantigen vaccines and RNA interference target tumor heterogeneity amid rising solid tumor incidences.[2][3][4] Timing aligns with post-2020 advances in mRNA tech (e.g., COVID vaccines) accelerating DNA/RNA platforms, plus FDA's push for breakthrough therapies amid immunotherapy market growth projected beyond $100B.[1] Favorable forces include precision oncology demand, combo therapy trends, and biopharma partnerships for solid tumors like ovarian cancer, where recurrence rates exceed 70%.[1][3] It influences the ecosystem by validating bi-shRNA for off-the-shelf personalization, potentially lowering costs versus fully bespoke CAR-T, and paving ways for KRAS-focused trials in hard-to-treat cancers.[3]
Gradalis is poised for commercialization with Vigil's Phase 3 readout potentially in 2025-2026, following VITAL-V initiation, alongside pipeline expansion into KRAS-driven tumors.[1][3] Trends like AI-optimized neoantigens and combo regimens with checkpoint inhibitors will amplify its momentum, with influence growing via approvals that standardize personalized immunotherapy. Success could position it as a mid-cap biotech leader, tying back to its core mission of patient-empowered cancer control through Vigil's proven trifecta.
